Skip to main content
SpringerLink
Log in

Important to achieve optimal exposure to antibacterials in the urinary tract in patients with urosepsis

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Wagenlehner FME, Weidner W, Naber KG. Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis. Clin Pharmacokinet 2007; 46(4): 291–305

    Article  PubMed  CAS  Google Scholar 

  2. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31(4): 1250–6

    Article  PubMed  Google Scholar 

  3. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45(8): 755–73

    Article  PubMed  CAS  Google Scholar 

  4. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345(19): 1368–77

    Article  PubMed  CAS  Google Scholar 

  5. Gluck T, Opal SM. Advances in sepsis therapy. Drugs 2004; 64(8): 837–59

    Article  PubMed  Google Scholar 

  6. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30(4): 536–55

    Article  PubMed  Google Scholar 

  7. Lyseng-Williamson KA, Perry CM. Drotrecogin alfa (activated). Drugs 2002; 62(4): 617–30

    Article  PubMed  CAS  Google Scholar 

  8. Singh N, Yu VL. Rational empiric antibiotic prescription in the ICU. Chest 2000; 117(5): 1496–9

    Article  PubMed  CAS  Google Scholar 

  9. Frimodt-Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 2002; 19(6): 546–53

    Article  PubMed  Google Scholar 

  10. Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001; 17(4): 331–41

    Article  PubMed  CAS  Google Scholar 

  11. Lubasch A, Keller I, Borner K, et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44(10): 2600–3

    Article  PubMed  CAS  Google Scholar 

  12. Naber K. Antibacterial activity of antibacterial agents in urine: an overview of applied methods. In: Bergan T, editor. Urinary tract infections. Basel, Freiburg, Paris, London, New York: Karger, 1997: 74–83

    Chapter  Google Scholar 

  13. Stein GE, Schooley S. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers. Int J Antimicrob Agents 2004; 24(2): 168–72

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Important to achieve optimal exposure to antibacterials in the urinary tract in patients with urosepsis. Drugs Ther. Perspect 23, 19–21 (2007). https://doi.org/10.2165/00042310-200723110-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200723110-00006

Search

Navigation